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Abstract
5-Hydroxymethylcytosine (5hmC) is lost in multiple human cancers, including colorectal cancer (CRC). Decreased
ten-eleven translocation 1 (TET1) messenger RNA (mRNA), but not other two TET family members, has been observed
in the colorectal cancer and is crucial for colorectal cancer initiation. Here, we show that nuclear localization of TET2
was lost in a significant portion of CRC tissues, in association with metastasis. In CRC cells, nuclear expression of TET2
were absent but not TET3. Nuclear export inhibitor can increase the 5hmC level in CRC cells, probably through
regulating TET2. Our results indicate a new mechanism of TET2 dysregulation in colorectal cancer.
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5-Hydroxymethylcytosine (5hmC) is lost in multiple hu-
man cancers, including colorectal cancer. Inactivation of
the ten-eleven translocation (TET) family members, the
DNA hydroxylases catalyze 5mC into 5hmC, was closely
related to the cancer initiation and progression. Re-
cently, F Neri et al. reported the downregulation of
TET1 messenger RNA (mRNA) expression level, but not
other two TET family members, in colon cancer and
showed that decreased TET1 mRNA was crucial for
colon cancer initiation and TET1 functioned as a tumor
suppressor by inhibiting the WNT pathway [1]. How-
ever, another group observed the decreased mRNA level
of all TET family members in the colorectal cancer [2].
These contradictory findings could be due to the inter-
fering by the stromal and infiltrating immune cells in
the tumor tissues, the unstable mRNA in the tissue sam-
ples, and the RNA degradation during the RNA extrac-
tion. Besides, it was reported that the reduced levels of
5hmC in colorectal cancers is not correlated with TET
mRNA levels [3], which indicates that dysregulation of
TET protein could play a vital role in colorectal cancer.
Thus, we analyzed both the mRNA and protein level of
the TET family members in our colorectal cancer
specimens.
Consistent with the finding of F Neri and another pre-
vious report [4], only TET1 was significantly decreased
in the colorectal cancer tissues and cell lines at mRNA
level (Additional file 1: Figure S1A and B). No detectable
TET1 protein was observed in the CRC cell lines with
low TET1 mRNA level (Additional file 1: Figure S1C),
indicating that the decreased TET1 mRNA level resulted
in low TET1 protein level in colorectal cancer. After
testing several commercial TET2 antibodies, TET2 anti-
body (ab94580) was used for the immunohistochemical
analysis of a CRC tissue array for the high sensitivity
and specificity of this antibody (Additional file 1:
Figure S1D). As shown in Fig. 1a, while normal and
some CRC tissues contain positive nuclear staining of
TET2, interestingly, a large portion of CRC tissues
showed loss of nuclear staining of TET2 (Fig. 1b).
After comparing TET2 nuclear expression with clin-
ical data, we found that loss of nuclear TET2 expres-
sion was correlated with a more aggressive distal
metastasis phenotype (P = 0.021) (Additional file 2:
Table S1). No difference in the protein expression
level and localization of TET3 between the normal
and cancer tissues was observed (Additional file 1:
Figure S1E). To confirm the finding of immunohisto-
chemical (IHC) analysis, we detected the TET2 protein ex-
pression in the CRC cell lines. Consistent to IHC data,
nuclear localization of TET2 was lost in 5 CRC cell lines,
1 lung cancer cell line, and 293T cells we tested (Fig. 1c).
However, strong nuclear localization of TET3, another
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TET family member expressed in CRC cells, was detected
in these cell lines. Also, we observed increased 5hmC level
in multiple CRC cell lines after treatment with the nuclear
export inhibitor, leptomycin B (LMB) (Fig. 1d). Knock-
down TET2 further demonstrated that increasing 5hmC
induced by LMB treatment was due to the TET2 protein
(Fig. 1e).
DNA methylation is a therapeutic target for cancer
treatment [5]. DNA hypermethylation occurs to the pro-
moter of tumor suppressor genes, resulting in decreased
expression of the tumor suppressor and cancer initiation
and progression [5]. Inhibitors of DNA methyltransfer-
ases like 5-azacytidine and 5-aza-2′-deoxycytidine have
been shown the efficacy in the treatment of multiple
cancers to induce the expression of the tumor suppres-
sor genes [6]. DNA hypermethylation of tumor suppres-
sor genes could be due to the loss of active DNA
demethylation which is consistent with global loss of
5hmC level in cancers [4, 7]. Thus, re-activation of the
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Fig. 1 Loss of TET2 nuclear expression in colorectal cancer. a Immunohistochemical analysis of TET2 in colorectal cancer samples and normal
mucosa tissues. Representative images of normal mucosa tissues (a), cytoplasmic expression of TET2 in CRC (b), nuclear expression of TET2 (c)
in CRC, and TET2 expression in the invasive marginal region of CRC (d) were indicated. Scale bar: 100 μm. b Distribution of TET2 subcellular
localization in normal mucosa tissues and colorectal cancer tissues. c Cytoplasmic (Cyto) and nuclear (Nuc) fractions of several cancer cells were
separated for Western blot analysis as indicated. The following antibodies were used for Western blot: TET2 (ab94580), TET3 (GTX121452), Lamin
A/C (CST #2032), and β-tubulin (Proteintech, 10068-1-AP). d Cells were treated with leptomycin B (LMB, 200 nM, 24 h), and then, DNA was
extracted for 5hmC detection and methylene blue (MB) staining. e LoVo cells were transfected with siRNA targeting TET2 for 2 days and then
treated with leptomycin B (200 nM, 24 h). DNA was extracted for 5hmC detection and methylene blue staining
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re-expression of the tumor suppressor genes. The nu-
clear export inhibitors is also a promising cancer treat-
ment drugs which have been shown to inhibit nuclear
export of tumor suppressors like TP53 [8]. Here, we
showed that LMB treatment can increase the global level
of 5hmC probably through regulating TET2 in the CRC
cell lines, which could promote the active demethylation
and expression of tumor suppressor genes. Our results
provided a novel mechanism that nuclear export inhibi-
tor functioning through restoring the 5hmC level and
potential expression of tumor suppressor genes which
need to be further studied in the future.
Several mechanisms have been reported for the dys-
regulation of TET2 in cancers, including mutation of
TET2 gene [9] and decreasing TET2 mRNA expression
level [10, 11]. Nuclear exclusion of TET1 protein was
found in the IDH1 wild-type gliomas [12]. Nuclear
translocation of TET2 was first reported in the B cells
[13]; furthermore, our results demonstrated that nuclear
translocation of TET2 was also dysregulated in colo-
rectal cancer, probably through the post-translational
modification. Since TET2 needs to interact with DNA
binding partners to regulate gene expression in the
nucleus, loss of TET2 nuclear expression impaired
TET2’s function. Thus, TET2 could also be a tumor
suppressor in colorectal cancer, and the tumor suppressor
function of both TET1 and TET2 was impaired in colo-
rectal cancer through different mechanism.
Additional files
Additional file 1: Figure S1. (A) The mRNA expression level of TET
family members in 9 paired normal mucosa tissues and colorectal cancer
tissues were detected by qPCR. (B) The mRNA expression level of TET
family members in normal colon cell line (CCD-841) and six colorectal
cancer cell lines were detected by qPCR. (C) The TET1 protein expression
level in the colorectal cancer cell lines were detected by western blot. (D)
Western blot analysis of several TET2 antibodies showed that the TET2
antibody (ab94580) used for IHC was specific for TET2 protein. FLAG-Tet2
was transfected into 293T cells by Lipofectamine 2000. 36h later, cells
were lysed and detected by using FLAG antibody and TET2 antibody. (E)
Immunohistochemical analysis of TET3 in colorectal cancer samples and
normal mucosa tissues. Representative images of normal mucosa tissue
and colorectal cancer tissue were shown. Scale bar: 100 μm. (PDF 419 kb)
Additional file 2: Table S1. Correlation of TET2 cytoplasmic expression
with CRC patients’ pathological features. (DOC 84 kb)
Additional file 3: Supplementary materials and methods. (DOCX 22 kb)
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